Last updated: June 19, 2026
Executive summary
No reliable, complete supplier/manufacturer set for “ENTERO VU 24%” can be produced from the information provided. Without an unambiguous drug identity (active ingredient name, strength/route, dosage form, and the specific label/market authorization), any supplier list would be speculative.
What is “ENTERO VU 24%” and which suppliers make it?
A supplier answer depends on identifying the exact pharmaceutical product behind the label “ENTERO VU 24%.” Many products use overlapping brand naming conventions across countries and formulations, and “24%” can refer to different actives or concentrations depending on jurisdiction.
Which fields are required to map suppliers accurately?
Supplier mapping for a branded pharmaceutical product typically requires at least:
- Active ingredient (generic name)
- Dosage form (powder, solution, capsule, suspension, etc.)
- Route of administration
- Country/market (e.g., India, EU, US, MENA)
- Marketing authorization holder (MAH) and/or NDA/ANDA/BLA equivalent dossier identity
- Orange Book / local equivalent registry listing (where applicable)
How many manufacturers supply ENTERO VU 24% and where are they located?
Counts of manufacturers and geography are derived from:
- Regulatory product listings (MAH, manufacturing sites)
- Marketing authorization dossiers and inspection records
- Distributor rosters in target markets
- Tender award documentation and import/export customs records
No authoritative source set is available from the provided input to enumerate those manufacturers.
What is the Orange Book status of ENTERO VU 24% (US exclusivity)?
“Orange Book status” is only meaningful if the US FDA product code and active ingredient are known. With the current product descriptor, there is no verifiable way to check:
- Listed drug entries
- Patent numbers and expiration dates
- Exclusivity codes
Which companies are challenging ENTERO VU 24% via Paragraph IV?
Paragraph IV challenges require:
- A specific FDA-listed reference product
- Confirmed ANDA filer and FDA case docket mapping
- Patent identifiers asserted in the notice
The provided input does not identify the reference product in a way that supports a litigation-risk mapping.
What formulation and manufacturing-method patents protect ENTERO VU 24%?
Formulation and manufacturing-method patent mapping depends on:
- Confirmed active ingredient and dosage form
- Patent family assignment to the brand’s MAH
- Jurisdictional patent publication sets
No such patent estate can be attributed to “ENTERO VU 24%” without unambiguous product identity.
What generic entry risks exist for ENTERO VU 24%?
Generic entry risks depend on:
- Regulatory exclusivity status (data exclusivity, 505(b)(2) exclusivity, etc.)
- Patent landscape (composition, formulation, method-of-use)
- Launch-history signals and supply chain bottlenecks
No authoritative status can be mapped from the current input.
Which suppliers handle ENTERO VU 24% distribution and tenders?
Distribution-supplier identification requires at least one of:
- Country distributor list tied to the authorized label
- Government tender procurement records
- Importer-of-record details from customs data
Those sources cannot be anchored to the current descriptor.
Key Takeaways
- A non-speculative supplier list for “ENTERO VU 24%” cannot be produced from the provided information.
- Supplier mapping requires unambiguous product identity tied to regulatory listings and/or authorization holders.
FAQs
- How do I verify the correct manufacturer for a branded drug with only a brand name?
- What regulatory fields identify the true marketing authorization holder for a branded product?
- How can I map suppliers using manufacturing site data instead of brand names?
- What data sources most reliably list distribution suppliers in a target country?
- How do I translate label strength (like “24%”) into a confirmed active ingredient dossier?
References
No sources were cited because no verifiable supplier identity for “ENTERO VU 24%” can be established from the provided input.
